Although MHC-II, canonically expressed by APCs, has been shown to play multiple key roles in antitumor immunity, tsMHC-II, expressed on various tumor cells, exhibits a better prognostic correlation with cancer patients, both with patient survival and with response to immunotherapy with anti-PD-1/anti-PD-L1 drugs. This evidence concerns the gene CD274 and neoplasm.